As a new approach to treatment, CGT is an important driver to lead the innovation of future medical methods.
BRL Medicine (Chinese：邦耀生物), an innovative pharmaceutical company focused on gene and cell therapy, announced its completion of a Series B financing round exceeding CNY 200 million (USD 28.32 million) on November 14. This funding round was led by Shanghai FTZ Fund (Chinese：上海自贸区基金), with the participation from Oriental Fortune Capital (Chinese：东方富豪), Tasly Capita (Chinese：天力士资本), Betta Biomedical Industry Fund (Chinese：贝达生物医药产业基金) and Gopher Asset Management (Chinese：歌斐资产).
BRL Medicine will continue to promote the transformation and implementation of cell and gene drugs and further accelerate its global R&D layout.
Founded in 2013, BRL Medicine is dedicated to developing and translating gene editing, cell therapy, and gene therapy for genetic diseases caused by gene mutations, relying on its technical strength and scientific research team in gene editing and immunology. The company has built five technology platforms with independent intellectual property, including the Gene Editing Technology Innovation Platform, the Hematopoietic Stem Cell Platform, the Quikin CAR-T Platform, the Universal Cell Platform and Enhanced T Cell Platforms, with many pipeline projects entering into the IND application stage.
CGT (Cellular and Gene Therapy) is an emerging industry that relies on developing cell and gene therapy technology. According to statistics, the global CGT market size was USD 2.08 billion in 2020, and it is expected to reach USD 30.54 billion in 2025 at a five-year compound annual growth rate of 71%.
The CGT-related enterprises include WuXi Advanced Therapies (Chinese：药明生基), OBiO (Chinese：和元生物), and GenScript Biotech (Chinese：金斯瑞生物).